Please Wait...

BioClinica Acquires Transenda International, LLC

– Adds Clinical Trial Management Software With Microsoft Office Interoperability –

March 26, 2010

March 26, 2010.   NEWTOWN, PABioClinica®, Inc., (NASDAQ: BIOC), a global provider of clinical trial management services, today announced its acquisition of substantially all of the assets of privately held TranSenda International, LLC ("TranSenda"). Headquartered in Bellevue, WA, TranSenda is a provider of clinical trial management software (CTMS) solutions and is a Microsoft Gold Certified Partner.

TranSenda's innovative suite of web-based, Office-Smart CTMS solutions and patent-pending integration technologies create efficiencies for trial operations through interoperability with Microsoft Office tools. With this acquisition, BioClinica enhances its ability to serve customers throughout the clinical research process with technologies that include improved efficiencies by reducing study durations and costs through integrated operational management.

"TranSenda brings a line of Office-Smart clinical trial management solutions to BioClinica that will become a part of our Microsoft Office-enabled delivery vision," said Mark Weinstein, CEO of BioClinica. "With the incorporation of TranSenda's technology, our customers will benefit from the compatibility and ease-of-use efficiencies that exist across the broader eClinical domain. This acquisition is an important step forward as we continue to advance our integrated eClinical solutions model and execute our strategy of bringing best-in-class technology and resources to our customers."

Mr. Weinstein continued "The acquisition of TranSenda not only enhances our portfolio of clinical trial technology, it also provides us intellectual property with thought leaders and domain experts in trial planning and management. We welcome Bob Webber and his team to BioClinica."

"We are excited to join BioClinica as it will provide us the ability to expand our market reach and delivery to the global marketplace and fulfill the demand for our technologies," said Robert Webber, President of TranSenda International. "We expect BioClinica's expertise, scope of quality customer relationships and their overall global presence will be catalysts to the growth of our technologies and market reach."

"Information workers in the life sciences industry are often challenged with working across many different systems throughout the clinical trial process," said Michael Naimoli, director of life sciences industry solutions, Microsoft Corp. "TranSenda has helped pharmaceutical companies address these problems, providing solutions that allow professionals to work within the familiar Microsoft Office environment. We're pleased that BioClinica customers will also benefit from these tools and continue to simplify the workflow and clinical trials information management process."

Under the terms of the agreement, BioClinica is purchasing substantially all of the assets of TranSenda for 577,960 shares of BioClinica unregistered common stock at closing. For 2010, BioClinica expects TranSenda to contribute approximately $1.0 million in service revenue and an operating loss of $500,000. Additional financial details will be provided when BioClinica releases its first quarter 2010 results as well as full year 2010 guidance, which will include TranSenda's contribution. Additional terms of the agreement will be disclosed on a Form 8-K to be filed the same day as this press release.

About Bioclinica

Bioclinica is an integrated clinical life science solutions provider, delivering powerful insight into clinical trial development, assuring greater client success in bringing medical therapies to market, for people around the world. Through deep medical, scientific and technology expertise, the company provides medical imaging and cardiac safety services; clinical adjudication; randomization and trial supply management and optimization; electronic and eSource data capture; site and patient payments; clinical trial management software; and drug safety solutions. Bioclinica’s global team of life science experts serve more than 500 pharmaceutical, biotechnology and device organizations – including the top 20 biopharmaceutical companies and leading CROs – through offices in North America, Europe, and Asia.

 

###

 

Media Contact
Nicole Klatsky
+1 (609) 865-5212

Learn more about Bioclinica at www.Bioclinica.com and in the Bioclinica Blog. Follow the latest company news and happenings on LinkedIn and Twitter.

LEARN MORE OR SPEAK WITH OUR EXPERTS

CONTACT US
Leader in Clinical Trial
Management Solutions

Successful clinical trials require the ability to see key details and uncover hidden insights. Bioclinica utilizes science and technology to bring clarity to clinical trials, helping companies to develop new life-improving therapies more efficiently and safely.

With many clinical trials slowed or terminated, investments in new technologies are difficult. Yet, a #CTMS with a… https://t.co/VRIhWWf4tE
Bioclinica (2 weeks ago)
With Bioclinica #CTMS, sponsors & CROs have access to a full-featured, scalable system - a single, centralized sour… https://t.co/7ACrv8cvuF
Bioclinica (2 weeks ago)
Now available: a DIY #EDC solution. From study start-up to close-out, Bioclinica EDC Solo is an efficient, cost-eff… https://t.co/vFhC7ITfZV
Bioclinica (3 weeks ago)
Reduce the number of user requirement iterations and UAT findings during the #IRT build process. With the agile app… https://t.co/TJt2sZlrFP
Bioclinica (3 weeks ago)
Don't compromise with manual systems and spreadsheets. As an entry-level system with phased implementation, Bioclin… https://t.co/qIpi1MESXw
Bioclinica (4 weeks ago)
According to our recent poll, 45% of respondents had neither a #CTMS nor an #eTMF system, while only 24% had both.… https://t.co/l4dKC7pBQo
Bioclinica (4 weeks ago)